Hua Medicine Files to Start US Trial of Novel Diabetes Drug
March 09, 2015 at 05:53 AM EDT
Hua Medicine of Shanghai has filed an Investigational New Drug (IND) application with the FDA to begin US clinical trials of its novel type 2 diabetes treatment, a 4th-generation glucokinase activator (GKA). In February, Hua filed to start a Phase II trial of sinogliatin in China, after reporting positive Phase Ib data. Hua in-licensed global rights to sinogliatin from Roche in 2011. In January, Hua completed a $25 million funding round to support the two trials. More details.... Stock Symbol: (SIX: ROG) Share this with colleagues: // //